Celldex Therapeutics (CLDX) Stock Price, Quote & News

Company Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhi...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 200 7500

Fax: 908 454 1911

Website: www.celldex.com

Address:

Perryville III Building, Suite 220 53 Frontage Road, Hampton, United States

free2dream May. 7 at 8:23 PM

$CLDX barzolvolimab will be bigger than $20B Dupixent. This will eventually be a $20B market cap company. Everyone loves a good comeback story and with the trial results being so superior, $CLDX price will appreciate BIG

0 · Reply

NJgolfer Apr. 30 at 10:51 PM

$CLDX big overhead resistance between $33.60 - $36. Probably not ready to breakout. Weekly MACD and Weekly Stochastics remain elevated but Chaikin MF/AD/OBV has turned down already. Once it eventually gets through $36, upside targets of $40 and $48

2 · Reply

Timefortendies77 Apr. 29 at 11:51 AM

$CLDX After trials finish this year, the market will wake up to the potential here---think of a XOLAIR on Steroids---we aren't talking about just suppression of the course of the disease/condition---we are talking about potentially changing the course of the disease/condition. Look at the people who stopped the drug and are still HIVE free---it is unprecedented. KIT drugs are basically like a Ferrari compared to the old Toyota Sedans of allergy meds.

0 · Reply

Estimize Apr. 28 at 1:00 PM

Wall St is expecting -1.15 EPS for $CLDX Q1 [Reporting 04/30 AMC] http://www.estimize.com/intro/cldx?chart=historical&metric_name=eps&utm_c

0 · Reply

RunnerSignals Apr. 28 at 3:30 AM

$INVA $CLDX $DNN $ILMN $NTCT all trading above ma50/200 with neutral-positive rsi that is early repricing not trapped capital

1 · Reply

Steve1545 Apr. 22 at 10:23 AM

$CLDX

0 · Reply

Estimize Apr. 21 at 1:00 PM

Wall St is expecting -1.20 EPS for $CLDX Q1 [Reporting 04/30 AMC] http://www.estimize.com/intro/cldx?chart=historical&metric_name=eps&utm_c

0 · Reply

IN0V8 Apr. 20 at 7:17 PM

$CLDX Barclays raises target price to $45 from $24

1 · Reply

Timefortendies77 Apr. 20 at 1:15 PM

$CLDX Moving on an upgrade but data is a long ways off......will be great once the data comes.

0 · Reply

Quantumup Apr. 20 at 10:37 AM

Barclays⬆️ $CLDX's to Overweight/$45, plus⬆️CSU/ClndU PoS to 85%/75% and peak adj'd rev ests to $1.4B/$541M and said: We are upgrading CLDX to OW from UW on conviction for successful Phase 3 in CSU, positive readthrough to PN; Price Target to $45 (from $24) $NVS $SNY REGN JSPR Here's what else Barclays had to say: https://x.com/Quantumup1/status/2046175445083672728?s=20

0 · Reply

Celldex sees funds sufficient to fund current planned operations through 2028

May 7, 2026, 4:01 PM EDT - 21 hours ago

Celldex Reports First Quarter Financial Results and Provides Corporate Update

2026-04-20T14:19:17.000Z - 18 days ago

A Top Wall Street Analyst ‘Can’t Ignore’ Celldex Stock (CLDX)

2026-04-20T09:20:08.000Z - 18 days ago

Celldex upgraded to Overweight from Underweight at Barclays

Apr 14, 2026, 3:30 PM EDT - 23 days ago

Celldex Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Apr 13, 2026, 4:01 PM EDT - 24 days ago

Celldex to Present at Upcoming Investor Conference

Apr 6, 2026, 10:53 AM EDT - 4 weeks ago

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 1, 2026, 9:48 PM EDT - 5 weeks ago

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

2026-04-01T20:11:56.000Z - 5 weeks ago

Celldex announces common stock offering, no amount given

Apr 1, 2026, 4:01 PM EDT - 5 weeks ago

Celldex Announces Proposed Public Offering of Common Stock

2026-03-27T14:35:13.000Z - 6 weeks ago

Celldex data shows improvements across six DLQI Domains in barzolvolimab trials

Mar 27, 2026, 10:30 AM EDT - 6 weeks ago

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

2026-03-23T09:45:08.000Z - 6 weeks ago

Celldex upgraded to Outperform from Peer Perform at Wolfe Research

Mar 10, 2026, 3:40 PM EDT - 2 months ago

Celldex Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 9:10 AM EST - 2 months ago

Celldex Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-02T11:46:48.000Z - 2 months ago

Celldex price target raised to $34 from $30 at Goldman Sachs

2026-03-01T16:35:06.000Z - 2 months ago

Celldex presents new data from Phase 2 ColdU, SD Open Label Extension

Feb 27, 2026, 2:45 PM EST - 2 months ago

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

2026-02-26T14:45:31.000Z - 2 months ago

Celldex price target raised to $44 from $43 at Morgan Stanley

2026-02-26T12:40:18.000Z - 2 months ago

Celldex price target raised to $68 from $58 at Stifel

Feb 25, 2026, 4:01 PM EST - 2 months ago

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

2026-02-25T12:27:17.000Z - 2 months ago

Celldex completes enrollment in Phase 3 studies of barzolvolimab

Feb 25, 2026, 7:01 AM EST - 2 months ago

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria

Feb 23, 2026, 8:01 AM EST - 2 months ago

Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile

Feb 11, 2026, 3:30 PM EST - 3 months ago

Celldex Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 9, 2026, 8:01 AM EST - 3 months ago

Celldex to Present at Upcoming Investor Conferences

2025-12-17T11:00:48.000Z - 5 months ago

Celldex price target raised to $24 from $21 at Barclays

2025-12-09T13:11:47.000Z - 5 months ago

Celldex announces initiation of Phase 3 trial of barzolvolimab

Dec 9, 2025, 8:01 AM EST - 5 months ago

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

Dec 2, 2025, 3:00 PM EST - 5 months ago

Celldex Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 13, 2025, 9:30 AM EST - 6 months ago

Celldex Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 11, 2025, 10:00 AM EST - 6 months ago

Celldex Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-11T10:25:14.000Z - 6 months ago

Celldex price target lowered to $21 from $25 at Barclays

Nov 10, 2025, 8:01 AM EST - 6 months ago

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

Sep 17, 2025, 5:11 AM EDT - 8 months ago

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Sep 9, 2025, 3:20 PM EDT - 8 months ago

Celldex Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 9:01 AM EDT - 8 months ago

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 19, 2025, 4:30 PM EDT - 9 months ago

Celldex Therapeutics Transcript: Study Update

Aug 19, 2025, 4:01 PM EDT - 9 months ago

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Aug 7, 2025, 4:01 PM EDT - 9 months ago

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 14, 2025, 10:48 AM EDT - 11 months ago

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

Jun 12, 2025, 6:01 PM EDT - 11 months ago

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

Jun 12, 2025, 6:00 PM EDT - 11 months ago

Celldex Therapeutics Transcript: Status Update

Jun 10, 2025, 4:01 PM EDT - 11 months ago

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

Jun 6, 2025, 8:01 AM EDT - 1 year ago

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

May 8, 2025, 4:01 PM EDT - 1 year ago

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 5, 2025, 4:01 PM EDT - 1 year ago

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

Mar 11, 2025, 1:00 PM EDT - 1 year ago

Celldex Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 1:50 PM EST - 1 year ago

Celldex Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 8:01 AM EST - 1 year ago

Celldex Therapeutics to Present at Upcoming Investor Conferences

Mar 3, 2025, 8:01 AM EST - 1 year ago

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

Mar 1, 2025, 12:45 PM EST - 1 year ago

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

Feb 27, 2025, 4:01 PM EST - 1 year ago

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Dec 19, 2024, 8:01 AM EST - 1 year ago

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Dec 3, 2024, 4:15 PM EST - 1 year ago

Celldex Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 20, 2024, 8:01 AM EST - 1 year ago

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Nov 12, 2024, 4:00 PM EST - 1 year ago

Celldex Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 6, 2024, 4:01 PM EST - 1 year ago

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Celldex Therapeutics Transcript: Status Update

Oct 26, 2024, 5:43 PM EDT - 1 year ago

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

Oct 25, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

Sep 25, 2024, 10:45 AM EDT - 1 year ago

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

Sep 20, 2024, 10:00 AM EDT - 1 year ago

Celldex Therapeutics Transcript: TD Cowen Chronic Urticaria Summit

Sep 17, 2024, 8:35 AM EDT - 1 year ago

Celldex Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 16, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 29, 2024, 4:30 PM EDT - 1 year ago

Celldex Therapeutics Transcript: Study Result

Jul 29, 2024, 4:01 PM EDT - 1 year ago

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Jul 16, 2024, 8:01 AM EDT - 1 year ago

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Jun 4, 2024, 4:01 PM EDT - 2 years ago

Celldex Therapeutics to Present at Jefferies Healthcare Conference

Jun 2, 2024, 9:01 AM EDT - 2 years ago

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

May 15, 2024, 8:01 AM EDT - 2 years ago

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

May 6, 2024, 4:01 PM EDT - 2 years ago

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 17, 2024, 8:01 AM EDT - 2 years ago

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Mar 8, 2024, 7:00 AM EST - 2 years ago

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 10:30 AM EST - 2 years ago

Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Feb 29, 2024, 9:14 PM EST - 2 years ago

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Feb 28, 2024, 4:01 PM EST - 2 years ago

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Feb 26, 2024, 7:01 AM EST - 2 years ago

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 25, 2024, 9:45 AM EST - 2 years ago

Celldex Therapeutics Transcript: Study Update

Feb 24, 2024, 2:05 PM EST - 2 years ago

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Feb 6, 2024, 4:01 PM EST - 2 years ago

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 5, 2024, 8:01 AM EST - 2 years ago

Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024

free2dream May. 7 at 8:23 PM

0 · Reply

NJgolfer Apr. 30 at 10:51 PM

2 · Reply

Timefortendies77 Apr. 29 at 11:51 AM

0 · Reply

Estimize Apr. 28 at 1:00 PM

Wall St is expecting -1.15 EPS for $CLDX Q1 [Reporting 04/30 AMC] http://www.estimize.com/intro/cldx?chart=historical&metric_name=eps&utm_c

0 · Reply

RunnerSignals Apr. 28 at 3:30 AM

$INVA $CLDX $DNN $ILMN $NTCT all trading above ma50/200 with neutral-positive rsi that is early repricing not trapped capital

1 · Reply

Steve1545 Apr. 22 at 10:23 AM

$CLDX

0 · Reply

Estimize Apr. 21 at 1:00 PM

Wall St is expecting -1.20 EPS for $CLDX Q1 [Reporting 04/30 AMC] http://www.estimize.com/intro/cldx?chart=historical&metric_name=eps&utm_c

0 · Reply

IN0V8 Apr. 20 at 7:17 PM

$CLDX Barclays raises target price to $45 from $24

1 · Reply

Timefortendies77 Apr. 20 at 1:15 PM

$CLDX Moving on an upgrade but data is a long ways off......will be great once the data comes.

0 · Reply

Quantumup Apr. 20 at 10:37 AM

0 · Reply

notreload_ai Apr. 20 at 9:34 AM

Barclays boosts $CLDX on strong drug outlook; higher success odds and sales expectations. https://notreload.xyz/xy/barclays-upgrades-celldex-to-overweight-raises-price-target/

0 · Reply

NJgolfer Apr. 18 at 5:13 PM

$CLDX up to new 52w highs this past week. Coming back to $40S in the future

0 · Reply

lucabrix Apr. 17 at 3:02 PM

$CLDX Nice!!!

0 · Reply

Timefortendies77 Apr. 13 at 1:45 PM

$CLDX 50-70 Q4, going to be a blockbuster, but just have to wait a bit.

0 · Reply

Merlintrader Apr. 11 at 8:43 AM

$CLDX Celldex Therapeutics ( $CLDX): the full April 2026 deep dive on barzolvolimab, pipeline breadth, financing, competition and what still has to go right https://www.merlintrader.com/celldex-therapeutics-april2026-deepdive/

0 · Reply

Timefortendies77 Apr. 9 at 3:50 PM

$CLDX Offering has closed but no data until Q4, so its just a long waiting period to the EXPLOSION if P3 is great.

1 · Reply

lucabrix Apr. 9 at 3:03 PM

$CLDX Reply!

0 · Reply

lucabrix Apr. 7 at 8:02 PM

$CLDX Celldex Therapeutics 1h We’re pleased to announce the closing of our $345M public offering. This will support the potential commercialization of barzolvolimab, if approved, for the treatment of CSU & the continued advancement of our novel antibody-based pipeline.

0 · Reply

topstockalerts Apr. 3 at 7:57 PM

Celldex Therapeutics Inc priced an underwritten public offering of 10.345M common shares at $29.00 per share, with a 30-day option for underwriters to purchase up to an additional 1.55M shares. Expected gross proceeds are ~$300M before fees and expenses. Closing is anticipated around April 6, 2026, subject to customary conditions. Proceeds, alongside existing cash, will support potential commercialization of barzolvolimab (for chronic spontaneous urticaria, if approved), continued pipeline development, expansion of its bispecific antibody platform, and general corporate purposes. Led by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor Fitzgerald, with LifeSci Capital and H.C. Wainwright & Co. as co-leads. $CLDX

0 · Reply

Arcides Apr. 2 at 10:46 PM

$CLDX held the offering price level today very good.

1 · Reply

OpenOutcrier Apr. 2 at 12:39 PM

$CLDX (-7.5% pre) Celldex prices $300 million stock offering at $29 per share - SI https://ooc.bz/l/97933

0 · Reply

AlertsAndNews Apr. 2 at 2:42 AM

$CLDX CLDX Celldex Announces Pricing of $300 Million Public Offering of Common Stock "today announced the pricing of an underwritten public offering of 10,345,000 shares of its common stock at a public offering price of $29.00 per share."

0 · Reply

Market Cap	2.70B
Revenue (ttm)	1.55M
Net Income (ttm)	-258.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-16,694.19%
Debt to Equity Ratio	0.00

Volume	242,224
Avg Vol	1,055,098
Day's Range	N/A - N/A
Shares Out	78.49M
Stochastic %K	56%
Beta	0.98
Analysts	Strong Sell
Price Target	$57.00